Merck (MRK) Depreciation & Amortization (CF) (2009 - 2026)

Merck (MRK) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $581.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 15.74% year-over-year to $581.0 million; the TTM figure through Mar 2026 stood at $3.0 billion (up 154.1% YoY), while the FY2025 annual figure was $3.0 billion, up 45.0% from the prior year.
• Depreciation & Amortization (CF) declined to $581.0 million in Q1 2026 per MRK's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.5 billion in Q4 2025 and bottomed at $67.0 million in Q2 2024.
• Historically, Depreciation & Amortization (CF) has averaged $474.5 million across 5 years, with a median of $448.0 million in 2022.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) sank 82.18% — and 2025, when it surged 579.1%.
• Merck's Depreciation & Amortization (CF) stood at $406.0 million in 2022, then gained by 16.75% to $474.0 million in 2023, then advanced by 9.28% to $518.0 million in 2024, then jumped by 188.22% to $1.5 billion in 2025, then slumped by 61.09% to $581.0 million in 2026.
• Business Quant data shows MRK's Depreciation & Amortization (CF) at $581.0 million in Q1 2026, $1.5 billion in Q4 2025, and $449.0 million in Q3 2025.